Clovis Oncology, Inc.
CLVS
CLVS was delisted on the 20th of December, 2022.
192 hedge funds and large institutions have $1.63B invested in Clovis Oncology, Inc. in 2018 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 70 increasing their positions, 61 reducing their positions, and 43 closing their positions.
222% more call options, than puts
Call options by funds: $86.3M | Put options by funds: $26.8M
15% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 61
9% less funds holding
Funds holding: 210 → 192 (-18)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
34% less capital invested
Capital invested by funds: $2.47B → $1.63B (-$839M)
37% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 43
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$39.2M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$29M |
| 3 |
State Street
Boston,
Massachusetts
|
+$22.7M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$19M |
| 5 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$18.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$31.4M |
| 2 |
DFO
Duquesne Family Office
New York
|
-$21.9M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$19.2M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$15.8M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$15.6M |
CLVS Hedge Fund Activity: Q3 2018 in Review
192 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Clovis Oncology, Inc. (CLVS) for Q3 2018, worth a combined $1.63B — down 34% from $2.47B a quarter earlier.
Sellers outnumbered buyers: 43 funds closed out of CLVS and 27 opened new positions — a net loss of 16 holders — while 61 trimmed existing stakes and 70 added.
The largest buyer was Armistice Capital, adding an estimated $39.2M. The largest seller was Jennison Associates, exiting entirely with an estimated $31.4M sold.
- 192 institutional investors held Clovis Oncology, Inc. (CLVS) as of Q3 2018, down from 210 in Q2 2018.
- Funds reported $1.63B of Clovis Oncology, Inc. stock for Q3 2018, down 34% quarter-over-quarter.
- 27 funds opened new Clovis Oncology, Inc. positions in Q3 2018 and 43 closed out, a net change of -16 holders.
- The largest Clovis Oncology, Inc. buyer in Q3 2018 was Armistice Capital, an estimated $39.2M added.
- The largest Clovis Oncology, Inc. seller in Q3 2018 was Jennison Associates, an estimated $31.4M sold.
Based on aggregated 13F filings for Q3 2018.